Silexion has completed toxicology studies for SIL204, a treatment being developed for pancreatic cancer. The company has received approvals to initiate a phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer from regulatory authorities in Germany and Israel. Additionally, Silexion has announced a reverse share split, with reports varying on whether it is 1-for-10 or 1-for-15.